Tagged with GE

Pharma Bart van de Kerkhof highlights how Covidien’s acquisition will drive Medtronic to new heights thanks to a broader product portfolio. Medtronic is already piloting projects and cooperating with key stakeholders to increase cost-savings and shape the Dutch healthcare system of the future, based on evolving partnerships with all stakeholders, and practical…

Pharma Anita Atema, General Manager of Celgene, reveals Celgene’s inspiring and concrete  initiatives that illustrate how a true willingness to cooperate with healthcare stakeholders and a remarkable effort of transparency can help to tackle the current difficulties in accessing the Dutch market, while implementing new innovative pricing models such as pay for benefit.…

Pharma Anna Van Poucke, Partner and Chairman at KPMG Healthcare in the Netherlands, explains how KPMG can helps its partners and clients move forward towards a better integrated, more efficient and smartly designed healthcare eco-system, while remaining at the forefront of the industry in terms of M&A, supply chain and cultural…

Pharma Francesco Carugi, Managing Director at Grifols Italy, discusses the company’s presence in the plasma, plasma products and plasma diagnostics segments, the impact of the liberalization of the Italian plasma market on their growth and business model and his commitment to driving change management to develop the affiliate’s future success. Grifols is…

Pharma Egypt is at the ‘golden stage’ for investment, claims Boehringer Ingelheim country head Mohamed El-Sahhar, who explains how the company is expanding their organization in Egypt ahead of an expansion into diabetes and oncology.  Egypt’s international image is still heavily influenced by the political instability of 2011 to 2013; what…

Pharma Amgen Netherlands is preparing to launch five new products next year, including their leading cardiovascular biotech product Repatha and recently announced the acquisition of the Dutch biotech Dezima. General manager Jasper van Grunsven explains the challenges of preparing for the upcoming year in the midst of structural changes to the…

Pharma Christian Deleuze reveals the impact of the acquisition by Sanofi in 2011; explains the profitability and global reach of the bio manufacturing facility in Lyon; and tells us that the current system does not capture the benefits that the next generation of gene therapy products deliver over time, transforming chronic diseases into…

Pharma Dr. Giorgio Pisani, President and CEO of IBSA Italy, talks about his founding of the company in 2001 and its rapid growth in the market through a combination of organic growth and acquisitions, as well as the current direction of the IBSA group and his ambitions for the company in…

Pharma Maikel Beerens, CEO and founder of Xilloc, a promising Dutch company that designs patient-specific implants, anatomical models and surgical guides for bone reconstruction or augmentation with the help of 3-D printing, explains how his company aims to provide patients worldwide with the tailor-made implants they deserve while reducing the overall socio-economic cost…

Pharma Michiel van der Veen, CEO of GenKey, a global player in biometric identity management based in Eindhoven, explains how both the healthcare industry and public health schemes could benefit from biometric identities to cut costs and improve funds allocation, and how GenKey aims to become the “Google of digital identity”…

Pharma Bert de Jong, General Manager Benelux at Genzyme, discusses the solutions Genzyme is offering to patients suffering from rare diseases and MS in the Benelux and how these treatments add value overall to society, as well as the company’s changing role in the Sanofi organization with the addition of the oncology and…

Pharma Pharmed Healthcare is the only Egyptian company to hold a License from the innovator to produce generic sofosbuvir, but faces competition from at least ten different companies in the market. Given your experience in trying to combat the hepatitis C virus (HCV), which is an epidemic in Egypt, what are some…